Clinical Trials | August 18, 2022
Sanofi updates on amcenestrant clinical development program
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
First and only PARP inhibitor to improve invasive disease-free survival in patients
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Subscribe To Our Newsletter & Stay Updated
